Lotus Eye Hospital Intrinsic Value
LOTUSEYE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹33.47 | ₹26.78 - ₹40.16 | -70.0% | EPS: ₹0.30, Sector P/E: 12x |
| Book Value Method | asset | ₹28.57 | ₹25.71 - ₹31.43 | -74.4% | Book Value/Share: ₹28.57, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹33.47 | ₹30.12 - ₹36.82 | -70.0% | Revenue/Share: ₹24.76, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹44.63 | ₹40.17 - ₹49.09 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹44.63 | ₹35.70 - ₹53.56 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹33.47 | ₹30.12 - ₹36.82 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹33.47 | ₹30.12 - ₹36.82 | -70.0% | Revenue Growth: 6.8%, Adj P/E: 8.3x |
| Graham Defensive Method | conservative | ₹33.47 | ₹30.12 - ₹36.82 | -70.0% | EPS: ₹0.30, BVPS: ₹28.57 |
Want to compare with current market value? Check LOTUSEYE share price latest .
Valuation Comparison Chart
LOTUSEYE Intrinsic Value Analysis
What is the intrinsic value of LOTUSEYE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Lotus Eye Hospital (LOTUSEYE) is ₹33.47 (median value). With the current market price of ₹111.58, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹28.57 to ₹44.63, indicating ₹28.57 - ₹44.63.
Is LOTUSEYE undervalued or overvalued?
Based on our multi-method analysis, Lotus Eye Hospital (LOTUSEYE) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.17 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 1.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.74x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Lotus Eye Hospital
Additional stock information and data for LOTUSEYE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹6 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹4 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |